Dive Brief:
- Mylan has started a voluntary nationwide recall on three lots of a commonly prescribed stomach ulcer drug after finding trace amounts of a probable human carcinogen, the drugmaker stated Wednesday.
- The recall is focused on three batches that were distributed in 2017 and 2018. Testing found low levels of NDMA, or N-nitrosodimethylamine, a likely carcinogen and environmental contaminant. Mylan said it had received no reports of related adverse events.
- The medicine, nizatidine, is approved as a short-term ulcer treatment as well as for the treatment of esophagitis and heartburn from gastroesophageal reflux disease, or GERD.
